Ensysce Biosciences ENSC
NASDAQ ENSC
$0.47 -0.04 (-7.84%)
At close: Oct 23, 2026 · 4:00 PM EDT

Ensysce Biosciences (ENSC) Long-Term Debt Repayments (2022 - 2024)

Updated

Ensysce Biosciences' Long-Term Debt Repayments was $485,190 in FY2024, down 51.5% from $1 million in FY2023.

Analysis

Ensysce Biosciences (ENSC) Long-Term Debt Repayments (2022 - 2024) Analysis & Trends

From FY2017 onward, Ensysce Biosciences has reported Long-Term Debt Repayments for 5 years.

  • Long-Term Debt Repayments shows a three-year compound annual growth rate of 1.2% (FY2021 to FY2024).
  • The FY2024 figure marks the lowest annual Long-Term Debt Repayments since FY2021.
  • Per Business Quant data, Long-Term Debt Repayments in earlier years was $1 million in FY2023 (-29.0%), $1.41 million in FY2022 (+201.1%) and $467,774 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 1.00 Mn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 2.00 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 2.46 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn -
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 17.00 Mn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn -
10 Ensysce Biosciences 1.20 Mn -10.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 485,190.00
Jun 30, 2023 584,857.00
Mar 31, 2023 415,351.00
Dec 31, 2022 1.14 Mn
API Access

Ensysce Biosciences Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=ENSC&period=max&api_key=YOUR_API_KEY